Outcomes with ibrutinib by line of therapy and post‐ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis

The efficacy of ibrutinib has been demonstrated in patients with chronic lymphocytic leukemia (CLL), including as first‐line therapy. However, outcomes after ibrutinib discontinuation have previously been limited to higher‐risk populations with relapsed/refractory (R/R) disease. The objective of thi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Am J Hematol
Hauptverfasser: O'Brien, Susan M., Byrd, John C., Hillmen, Peter, Coutre, Steven, Brown, Jennifer R., Barr, Paul M., Barrientos, Jacqueline C., Devereux, Stephen, Robak, Tadeusz, Reddy, Nishitha M., Kipps, Thomas J., Tedeschi, Alessandra, Cymbalista, Florence, Ghia, Paolo, Chang, Stephen, Ninomoto, Joi, James, Danelle F., Burger, Jan A.
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley and Sons Inc. 2019
Schlagworte:
Research Articles
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6593416/
https://ncbi.nlm.nih.gov/pubmed/30767298
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.25436
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge